R
  • 773.714.0705
  • Home
  • About Us
  • Specialty
  • Activities
    • Live
    • Online
  • Outcomes & Toolkits
New User? Login
Certificate Use Certificate Code

Overview

Multidrug Resistant Bacteria – An Ongoing Global Healthcare Challenge

Multidrug Clinical Commentary

SHARE WITH COLLEAGUE

Activity URL:

https://www.achlcme.org/detail/3313/Multidrug-Resistant-Bacteria-–-An-Ongoing-Global-Health...

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Multidrug Resistant Bacteria – An Ongoing Global Healthcare Challenge
Format
Clinical Commentary
Time to Complete
1.00 hr(s).
Release Date
June 30, 2016
Expires On
June 30, 2017

Multidrug resistant gram-negative bacteria represent an ongoing global healthcare challenge, with changing epidemiology and resistance patterns resulting in increased morbidity and mortality rates among hospitalized patents. This activity will review the impact of extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing bacteria and present comparative data on current and emerging therapies to develop strategies for initial therapy and optimal outcomes. Strategies to optimize initial antimicrobial therapy for improved outcomes will be provided.

This activity is intended to educate physicians, nurses, pharmacists, and other clinicians involved in the treatment of multidrug resistant infections.

Upon completion of this activity, participants should be able to:
• Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens
• Summarize the salient features and critical differences amongst available antibiotics and those in development for use against multidrug resistant gram-negative bacteria
• Describe strategies to optimize initial antimicrobial therapy to ensure effectiveness of antibiotics and reduce the development of resistance
• Discuss the interventions with the potential to reduce inappropriate use of antibiotics and improve outcomes in patients with resistant bacterial infections

This activity is supported by an educational grant from Merck & Company. 

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem while viewing any media (audio/video).
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
6. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

James Lewis, PharmD (Faculty)
Clinical Pharmacist
Antimicrobial Management Team
Department of Pharmacy Services
Oregon Health & Science University
Portland, OR

Carlene A. Muto, MD, MS (Faculty)
Associate Professor of Medicine
Medical Director of Infection Control 
Center for Quality Improvement and Innovation
UPMC Health System
Pittsburgh, PA 

Marlene Hilton (Moderator)

ACHL requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity. 

Disclosures of the following financial relationships have been provided:

James Lewis, PharmD
Consultant: Astellas, Accelerate Diagnostics, Achaogen, Merck, The Medicines Company, Allergan

Carlene A. Muto, MD, MS
Nothing to disclose

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The faculty in this activity may discuss investigational uses of novel therapies under investigation for multidrug resistant bacterial infections.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation.  To receive credit, 70% must be achieved on the post-test.  A certificate of participation will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, please contact Michelle Forcier at mforcier@achlcme.org

Physicians
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

ACHL is authorized by IACET to offer 0.1 CEU for this program. 

The Academy for Continued Healthcare Learning (ACHL) has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET).  In obtaining this accreditation, ACHL has demonstrated that it complies with the ANSI/IACET Standard which is recognized internationally as a standard of good practice. As a result of the Authorized Provider status, ACHL is authorized to offer IACET CEUs for programs that qualify under the ANSI/IACET Standard.  

IACET CEUs are accepted by the American Nurses Association. Contact your licensing agency for details.

Pharmacists

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

This activity has been approved for 1.0 contact hour.

ACPE Universal Activity Number: 0396-0000-16-047-H01-P
Activity Type(s): Knowledge
Release Date: 6/23/16
Expiration Date: 6/23/17

Michelle Forcier
mforcier@achlcme.org
Related Activities
View All Activities

You are being redirected to another site.


footer-logo

308 S. Jefferson St.,
Suite 312,
Chicago, IL 60661

  • Phone: 773.714.0705
  • Fax: 773.714.0707
  • Home
  • Specialty
  • Sitemap
  • Privacy Policy
  • Contact Us
  • Follow us on Twitter
  • Like us on Facebook
  • Follow us on LinkedIn

Copyright © 2025 Academy for Continued Healthcare Learning. All Rights Reserved.

Processing...
×